Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Refractory Metastatic Colorectal Cancer: full-pipeline trial registry
1 of 2 indexed Refractory Metastatic Colorectal Cancer trials are currently recruiting.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Refractory Metastatic Colorectal Cancer: 2 US clinical trials tracked, 1 recruiting.
Refractory Metastatic Colorectal Cancer is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Delcath Systems, running 1 of these trials.
Enrollment posture brief
Registry condition refractory-metastatic-colorectal-cancer
OPEN 1 | RECR 50% | LATE 1 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Refractory Metastatic Colorectal Cancer lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Refractory Metastatic Colorectal Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Refractory Metastatic Colorectal Cancer is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
Delcath Systems
NCT06607458
Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients
Taiho Oncology
NCT04737187
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Refractory Metastatic Colorectal Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Refractory Metastatic Colorectal Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Refractory Metastatic Colorectal Cancer page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Refractory Metastatic Colorectal Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Delcath Systems sponsors the most Refractory Metastatic Colorectal Cancer trials on record, review their full trial history before evaluating a specific study. See Delcath Systems's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Refractory Metastatic Colorectal Cancer condition card totals 2 registered trials; most-linked intervention Trifluridine/Tipiracil; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.